Estrogen receptor beta agonist - Bayer Healthcare PharmaceuticalsAlternative Names: ERβ agonist
Latest Information Update: 21 Mar 2011
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Mechanism of Action Estrogen receptor beta agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Menopausal syndrome
Most Recent Events
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals